The incidence of factor VIII inhibitors in patients with severe hemophilia A
- 1 January 1995
- book chapter
- Published by Springer Nature
- Vol. 386, 35-45
- https://doi.org/10.1007/978-1-4613-0331-2_3
Abstract
Inhibitor development is a serious complication of hemophilia A treatment. Although studies of inhibitor prevalence had been published earlier,1–3 the possibility that there is increased risk of inhibitor formation with different Factor VIII (F.VIII)-containing products was first raised when heat-treated concentrates were introduced. However, this concern was quickly dropped when it was apparent that heat treatment was necessary to inactivate HIV. As a result, no systematic study during the 1980s directly compared heat treated and non-heat treated F.VIII concentrates.Keywords
This publication has 22 references indexed in Scilit:
- Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIIIThe Lancet, 1993
- Current Status of Clinical Studies of Recombinant Factor VIII (Recombinate) in Patients With Hemophilia ATransfusion Medicine Reviews, 1992
- Incidence of development of factor VIII and factor IX inhibitors in haemophiliacsThe Lancet, 1992
- Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia ANew England Journal of Medicine, 1990
- Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcomeBritish Journal of Haematology, 1990
- Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodiesBritish Journal of Haematology, 1990
- Inhibitors to monoclonal antibody purified factor VIIIThe Lancet, 1990
- Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrateThe Lancet, 1990
- Use of Recombinant Antihemophilic Factor in the Treatment of Two Patients with Classic HemophiliaNew England Journal of Medicine, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958